Comparison of Cost Effectiveness Analysis (CEA) for Chronic Disease Management Program (Prolanis) Participants and Non Participants (Non Prolanis) on BPJS Kesehatan Diabetes Patients Year 2014 – 2016
Indrianti Wakhyuni1, Dan Aty Herawati2
1Indrianti Wakhyuni, Magister Manajemen Universitas Mercu Buana.
2Dan Aty Herawati, Magister Manajemen Universitas Marcu Buana.
Manuscript received on 07 May 2019 | Revised Manuscript received on 19 May 2019 | Manuscript Published on 23 May 2019 | PP: 935-941 | Volume-7 Issue-6S5 April 2019 | Retrieval Number: F11610476S519/2019©BEIESP
Open Access | Editorial and Publishing Policies | Cite | Mendeley | Indexing and Abstracting
© The Authors. Blue Eyes Intelligence Engineering and Sciences Publication (BEIESP). This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Abstract: An estimated of 5.1 million people in the world aged between 20 and 79 years die of diabetes mellitus in 2013 and the cost of health services for people with diabetes is 2-3 times higher than those who are not (International Diabetes Federation, 2015). In Indonesia National Health Insurance Program (JKN), diabetes mellitus patients are being managed in a Chronic Disease Management Program called PROLANIS. The purpose of this study is to analyze and compare the cost-effectiveness of diabetes mellitus which are managed with PROLANIS from those which are not (NON PROLANIS). The analysis and comparison run for outpatient, inpatient, emergency, and patients with complication. The calculation of cost effectiveness analysis (CEA) is done through the calculation of ACER and ICER. Research methodologies used are descriptive analysis, Kolmogorov Smirnov’s normality test, and Mann Whitney non parametric test. The result shows significant differences between costs and cases that are managed under PROLANIS and NON PROLANIS for outpatient, inpatient, and emergencies, while for patients with complications there is no significant difference of cases. PROLANIS is proven to be more cost-effective in managing diabetes mellitus than NON PROLANIS.
Keywords: Diabetes Mellitus, Prolanis, Non Prolanis, Cost Effective.
Scope of the Article: Disaster Management